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Abstract 
Background: Paraoxonase-1(PON1), a high-density lipoprotein (HDL) associated enzyme, is believed to contribute in the 
pathogenesis of coronary artery disease (CAD). The aim of this study was to evaluate the association of PON1 promoter C 
(-107)T polymorphism with the extent of coronary artery stenosis in Iranian patients. 
Methods: The RFLP analysis for determination of the C(-107)T genotype distribution and measurement of serum PON1 ac-
tivities (Paraoxonase and Arylesterase) were performed in 99 patients. They were undergone coronary angiography to deter-
mine the number of stenotic vessels and classified into three groups: single vessel disease (SVD), two vessels disease (2VD) 
and three vessels disease (3VD).  
Results: The C(-107)T polymorphism was significantly associated with serum arylesterase activity but not with 
paraoxonase activity. The CC and TT genotypes distributed inversely in SVD as compared with 3VD group. Moreover, the 
CC high activity genotype frequency decreased with increase of stenotic vessels in patients. 
Conclusion: The reduced arylesterase activity as a function from the weak promoter activity increases the stenosis severity, 
so that, we assume it is one of the progressive factors of atherosclerotic process in stenotic vessels.      
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Introduction 
Paraoxonase-1(PON1), a 45-kDa glycoprotein 
(1), is a calcium dependent esterase that hydro-
lyzes thiolactones (2), arylesters such as phenyl 
acetate and organophosphates such as paraoxon, 
sarin, diazoxon and soman (3). The role of serum 
PON1 as one high-density lipoprotein (HDL) as-
sociated enzyme have studied in several dis-
eases (4-7). Coronary artery disease (CAD) is 
thought to begin with inflammatory reactions at 
the endothelial level, and oxidized LDL is be-
lieved to be center to progression of atheroscle-
rosis (8). Paraoxonase (PON1) as an antioxidative 
enzyme protects LDL from oxidation by the 
hydrolysis of lipoperoxides (9). Thus, it has been 
suggested that the serum PON1 activity is mark-
edly related with CAD risk in human (10). Nu-
merous polymorphisms in the coding region and 
promoter of the PON1 gene affect the enzy-
matic activities (arylesterase and paraoxonase) 
(11-12). The role of coding region polymorphisms 
in predicting atherosclerosis remains controver-
sial; some studies revealed a significant associa-
tion between these polymorphisms and CAD risk, 
while others reported a lack of association (13-
14). Several studies have also focused on the 
PON1 promoter polymorphisms and shown that 
the C (-107) T position within Sp1 consensus is 
related with CAD risk. The TT genotype associ-
ated with low arylesterase activity has been sug-
gested as a risk factor of CAD by several in-
vestigators (15) but not by others (16).  
The present study was to evaluate the serum PON1 
activities  and  C (-107) T polymorphism to define  
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whether polymorphic site as an independent fac-
tor was associated with the severity of coronary 
artery stenosis in Iranian patients.  
 
Materials and Methods 
Ninety nine subjects with CAD were selected 
from September 2006 to March 2007. Subjects 
who underwent coronary angiography in Te-
hran Rajaee Cardiovascular Center for detec-
tion of the extent of stenosis in coronary artery 
vessels were recruited during the course of a 
study of genetic risk factors for CAD according 
to a designed protocol. Patients were included 
at least a 70% stenosis in a major epicardial ar-
tery and subdivided into three groups: single ves-
sel disease (SVD), two vessels disease (2VD) 
and three vessels disease (3VD). Participants with 
hepatic or renal disease, cardiomyopathy, conges-
tive heart failure and acute myocardial infarction 
within the last three months were excluded from 
the study. Medical history, drug intake and demo-
graphic data of the study population were col-
lected on a questionnaire. Blood pressure, weight 
and height were also recorded.  
Blood was drawn from all subjects after an 
overnight fast. Serum was separated immedi-
ately and stored at -20 ºC. Genomic DNA was 
extracted from whole blood by the method of 
Miller et al. (17) and stored at -20 ºC.  
Plasma total cholesterol and triglycerides were 
measured by routine enzymatic methods. HDL-
cholesterol was determined after precipitation of 
the apoB-containing lipopoproteins. LDL-cho-
lesterol was calculated using Friedewald for-
mula (18). 
Paraoxonase-1 activities toward phenylacetate 
(Sigma Co, USA) and paraoxon ethyl (Sigma Co, 
USA) were determined spectrophotometrically 
at 270 nm and 412 nm, respectively. One unit 
of arylesterase activity was equal to one µmol of 
phenylacetate hydrolyzed per ml per minute. In 
addition, one unit of paraoxonase activity provided 
one nmol p-nitrophenol per ml per minute (19). 
The C(-107)T genotype frequency was deter-
mined with the RFLP analysis method as de-
scribed by Brophy et al. (20). 
The data were analyzed using SPSS 13.0 and 
presented as mean±SD. The PON1 arylesterase 
activity differences between genotypes were also 
evaluated by analysis of variance (ANOVA) 
followed by post hoc testing with Turkey's test. 
Categorical variables were compared between 
groups by the χ2 test. P< 0.05 were considered 
to be significant for statistical tests. 
 
Results 
Ninety nine subjects (73 men and 26 women) 
were studied (Table 1). Patients were taking 
aspirin and lipid- and blood pressure-lowering 
medications. No significant differences in mean 
age, BMI, blood pressure and lipid profiles 
were found between the patient groups. 
The mean of PON1 activity toward paraoxon 
ethyl was insignificantly different among the geno-
types, although, the TT genotype had a lower 
activity than did the other genotypes (Table 2). 
In contrast, the increase of PON1 activity to-
ward phenyl acetate was significantly associated 
with the number of -107 C allele. We observed 
a reverse and significant association between the 
increase of -107T allele and decreased aryles-
terase activity in the SVD and 3VD groups.  
The results were significantly showed reverse 
association between the number of stenotic ves-
sels and PON1 arylesterase (P= 0.002) and 
paraoxonase (P= 0.038) activities as evaluated 
by ANOVA (Fig. 1). The arylesterase and 
paraoxonase activities decreased 22% and 20%, 
respectively in 3VD as compared with SVD.  
The genotype distribution of C (-107)T polymor-
phism are reported in Fig. 2. The CC frequency 
as a high activity genotype was higher in the 
SVD as compared with 2VD and 3VD, while 
the frequency of low activity genotype (TT) had 
direct association with the stenosis severity in 
coronary arteries.  
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Table 1: Characteristics of patients with coronary artery disease 
 
Patients (n= 99) 
Parameter 
SVD 2VD 3VD All 
Age (yr) 59.34±9.42 55.12±9.06 58.34±9.38 58.31±9.21 
Sex (Men/Women) (19/16) (12/6) (42/4) (73/26) 
BMI (kg/m2) 26.81±3.32 25.17±6.4 25.8±5.06 26.23±4.37 
SBP(mmHg) 123.8±1.6 126.0±0.9 121.5±1.14 123.3±1.3 
DBP(mmHg) 77.1±0.4 80.0±0.7 78.4±0.3 78.0±0.4 
Cholesterol(mg/dl) 173.14±37.04 166.44±39.07 170.17±36.28 170.51±36.00 
Triglycerides(mg/dl) 139.40±72.83 138.63±49.82 151.09±58.30 146.12±64.23 
HDL-C(mg/dl) 41.49±9.81 36.44±5.60 39.07±9.42 39.44±9.16 
LDL-C(mg/dl) 94.44±25.97 90.87±21.56 93.45±23.07 93.24±22.89 
     SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index 
 
Table 2: The C(-107)T genotype frequency and PON1 paraoxonase and arylesterase activities in subjects 
 
Patients (Mean±SD) Enzyme 
activity 
(U/mL) 
Genotype 
(Frequency) SVD(35)           2VD(16)          3VD(46)           All (99) 
Paraoxonase 
      
 
 
Arylesterase 
      
 
 
 
CC(0.27) 
CT (0.48) 
TT(0.25) 
P-Value 
CC (0.27) 
CT (0.48) 
TT (0.25) 
P-Value 
255.91±94.41 
290.71±113.33 
225.10±76.81 
NS 
122.53±28.04 
105.62±24.39 
65.76±19.44 
<0.01 
264.40±97.55 
270.43±52.70 
198.91±45.71 
NS 
109.58±15.62 
83.58±15.62 
82.34±21.00 
NS 
254.77±89.26 
215.59±73.31 
211.84±69.07 
NS 
106.28±13.13 
87.03±23.80 
76.13±28.10 
<0.05 
258.01±90.22 
249.6±95.13 
210.76±63.35 
NS 
109.79±27.40 
96.24±25.87 
76.24±25.01 
<0.01 
 
Fig. 1: Relationship between PON1 arylesterase and paraoxonase activities and the number of stenotic vessels. *, **, P< 
0.05 between SVD and 3VD groups 
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Fig. 2: The C(-107)T genotype distribution among CAD patients 
 
Discussion 
The present study confirmed association between 
the PON1 gene promoter C(-107)T polymor-
phism and extent of coronary artery stenosis in 
Iranian patients with CAD. Since, no significant 
differences were observed between the charac-
teristics of patient groups, thus, the results were 
brought about the changes of C(-107)T poly-
morphism and the PON1 activities.  
The role of some common polymorphisms such 
as -107, -162, -824 and -907 within the 5' re-
gion of the PON1 gene have studied with CAD 
risk by several investigators (21-22). In vitro 
expression studies have been demonstrated that 
the -107 position occurs within a consensus se-
quence for the transcriptional factor Sp1 and is 
related with the PON1 gene expression (23). 
Moreover, the serum arylesterase activity has in-
dicated as a function from the PON1 promoter 
activity, while the paraoxonase activity has in-
volved with the Q192R polymorphism within 
the PON1 coding region (24). 
In agreement with these studies, our data showed a 
significant association between the number of C-
107 allele and the serum arylesterase activity, 
so that the inverse patterns from distribution of 
the TT and CC genotypes found among the 
patient groups. The results showed no association 
between paraoxonase activity and C(-107)T poly-
morphism. It was logical due to the demon-
strated association between the PON1 promoter 
polymorphism with arylesterase activity but not 
with paraoxonase activity (24). 
In our patients, the arylesterase and paraoxonase 
activities decreased in agreement with the steno-
sis severity due to the weak promoter activity 
associated with the -107T allele. These results 
hypothesize that the PON1 activity changes an-
tioxidative capacity, this, in turn, affects the ex-
tent of stenosis in coronary arteries. 
In conclusion, the C(-107)T polymorphism is as-
sociated with the PON1 arylesterase activity but 
not with paraoxonase activity. Furthermore, the 
reduced arylesterase activity as a function from 
the weak promoter activity increases the sever-
ity of CAD, so that, we assume it is one of the 
progressive factors of atherosclerotic process in 
stenotic vessels.   
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